Sensorion, Novasep ink gene therapy agreement - The Science Board

-
By The Science Advisory Board staff writers

October 27, 2020 -- Sensorion and Novasep have signed an agreement for the manufacturing of adeno-associated virus (AAV) vectors covering a gene therapy program that targets OTOF, the gene encoding the otoferlin protein. Mutations of OTOF can lead to severe congenital hearing loss.

OTOF-GT, Sensorion's most advanced program, aims to restore the expression of otoferlin in the inner hair cells of the ear, where it plays an essential role in hearing.

Under the terms of the agreement, Novasep will be in charge of developing and manufacturing the two AAV vectors designed for Sensorion's OTOF-GT product and will supply drug product batches to support preclinical and clinical studies. Development and manufacturing activities include cell culture, AAV expression, purification, aseptic distribution, and quality control.

Related Reading


Copyright © 2020 scienceboard.net

Last Updated ls 10/27/2020 1:29:57 PM



Comments

Post a Comment

Popular posts from this blog

Well-liked Medicare plan vs. higher-ranked providers - ChicagoNow

-
Image
Medicare Open Enrollment ends December 7. The easy choice is to stay with all-in-one Medicare Advantage instead of switching to Traditional Medicare plus a supplement and drug plan. The hard one is whether to switch between Medicare Advantage plans, from a well-liked one to one accepted at a so-called top-10 hospital. Humana Gold Plus, a Medicare Advantage HMO, has served me well for five years. Hearing aids cost me only $10 after its $2,000 allowance. Routine doctor and dentist appointments and my medication cost nothing. But Humana Gold Plus is not accepted by Northwestern Memorial Hospital, the nearby hospital that US News & World Report ranks as the tenth best in the country, or by Northwestern Medicine physicians. My primary care physician is in an Advocate Medical Group. If I were hospitalized, it would be at Advocate Illinois Masonic Medical Center. If I had a serious illness, I’d see specialists in Advocate’s network. Illinois Masonic is not a second-rate hospital, and...
Read more

Minnesota veterans blame 3M's 'defective' ear plugs for hearing damage - KSTP

-
Image
3M did not admit any wrongdoing as part of that settlement. Read 3M's full statement on the ear plugs here. "We deny this product was defectively designed," a company spokesperson said in a statement to 5 INVESTIGATES, adding they will "defend against the allegations in these lawsuits." More than 630 lawsuits have been filed and will be heard in a federal court in Florida. An attorney involved with the multi-district litigation says roughly 30 have been filed by veterans who live in Minnesota. Constant ringing Sarah Kay Carlson, an Army veteran from St. Paul, filed her lawsuit in April, claiming 3M exposed her and thousands of other Marines and soldiers to "extremely dangerous and disabling noise." 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (PDF) 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (Text) Carlson, who was deployed as part of Operation Iraqi Freedom in the late 2000s, provided security to convoys t...
Read more

Sickle Cell Disease (SCD): Practice Essentials, Background, Genetics

-
Image
hemophilia c factor 11 :: Article Creator Regeneron Reports Fourth Quarter And Full Year 2023 Financial And Operating Results Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenuesincreased 14% Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022;excluding Ronapreve(a), revenuesincreased 12% Fourth quarter 2023 Dupixent®global net sales(recorded by Sanofi) increased 31% to $3.22 billion versus fourth quarter 2022; full year 2023 Dupixent global net sales increased 33% to $11.59 billion versus 2022 Fourth quarter 2023 U.S. Net sales for EYLEA®HD and EYLEA®were $1.46 billion, including $123 million from EYLEA HD; full year 2023 U.S. Net sales for EYLEA HD and EYLEA were $5.89 billion, including $166 million from EYLEA HD following its August 2023 FDA approval Fourth quarter 2023 Libtayo®global n...
Read more